logo
When a Vaccine Safety Trial Becomes Unethical

When a Vaccine Safety Trial Becomes Unethical

New York Times16-05-2025

The Department of Health and Human Services last week announced a new standard for testing the safety of vaccines, a 'radical departure from past practices.'
All new vaccines will be evaluated against a placebo, an inert look-alike that serves as a point of comparison, the department said. Health Secretary Robert F. Kennedy Jr., as well as many anti-vaccine groups, has long argued that placebo-controlled trials were the only way to fully understand vaccine side effects.
To scientists who have spent their careers evaluating vaccines, the plan did not seem so radical. New vaccines are often tested against a placebo in clinical trials. One researcher has created a crowdsourced spreadsheet of more than a hundred examples.
But it also concerned vaccine experts that Mr. Kennedy seemed not to recognize the circumstances when placebo groups are neither ethical nor practical. The idea is widely accepted by scientists and enshrined in ethics frameworks for medical research.
'He's asking for something that's not ethical,' said Arthur Caplan, a leading bioethicist at the New York University Grossman School of Medicine.
Why Are Placebos Used in Vaccine Trials?
Randomized placebo-controlled trials are often described as the 'gold standard' of research: they allow scientists to tease out whether the effects they observe result from the drug itself or some other factor, such as the expectation of treatment.
Patients in trials of drugs for depression or pain, for example, often report feeling better even if they haven't received the treatment — the so-called placebo effect.
In vaccine trials, researchers also use placebos, often shots of a saline mixture, to help quantify behavioral and psychological changes that might arise from participants knowing whether or not they received the real vaccine.
Had some participants during the Covid-19 vaccine trials known they didn't get the actual vaccine, for example, they might have avoided the virus by staying home, potentially skewing data about infection rates.
Similarly, simply believing that they have gotten the real shot can make trial subjects more attuned to possible side effects and more likely to report them.
One study found that nearly a third of participants who received a harmless placebo during Covid vaccine trials reported side effects, most commonly headaches and fatigue.
Why Don't Some Trials Include Placebos?
Placebo-controlled trials, which may last years and cost tens of millions of dollars, are not always feasible or necessary, especially for vaccines that are updated every year, like the flu shot.
'By the time you're done with that trial, it would be two years later and your vaccine is already outdated,' said Dr. Daniel Salmon, director of the Institute for Vaccine Safety at the Johns Hopkins Bloomberg School of Public Health. 'Pragmatically, it's just not possible.'
Instead, updated flu shots — which are only slightly tweaked each year — are tested in animals to see whether they produce an immune response similar to earlier versions of the vaccine, which have extensive safety and efficacy data.
There are also ethical reasons why using a placebo may not be appropriate. Perhaps the clearest example comes from the polio vaccine trial in 1954.
Hundreds of thousands of children had volunteered, eager for a chance at protecting themselves against a devastating disease that was sweeping through classrooms and communities, causing irreversible paralysis and death.
More than 200,000 of those children were randomly assigned to the placebo group, receiving doses of saline water instead of the vaccine. By the end of the trial, 16 of those children had died of polio.
All of the children who received the vaccine survived.
Bioethicists and scientists believe that the saline shots were ultimately necessary to prove the vaccine's effectiveness. And since there was no alternative vaccine or treatment at the time, the children assigned to the placebo were not at higher risk than the average American primary schooler.
But institutional review boards, which are charged with evaluating the ethics of medical studies before they start, carefully weigh the experimental benefits of using a placebo against their responsibility to protect the participants in the trial.
'It is better to do a randomized, placebo-controlled trial,' said Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia. 'But there is a certain cruelty to that.'
How Are Vaccines Tested Without a Placebo?
In general, review boards abide by the principle that placebos are not appropriate if there is a 'proven intervention' that already exists that has an established record of safety. In those cases, researchers will compare the new vaccine with the standard of care.
For example, during the development of the first vaccine for HPV, a sexually transmitted virus that causes nearly all cases of cervical cancer, researchers compared its efficacy and safety with that of a placebo.
The vaccine was a huge success. The shot reduced the risk of cervical cancer by 70 percent.
Years later, when researchers developed a vaccine that they believed would protect against five additional types of the virus, they could not ethically test it against a placebo. Doing so would have meant withholding a safe and very effective vaccine from half the participants.
Instead, scientists measured how much more effective the new HPV shot was than the original vaccine.
Michael Osterholm, an epidemiologist at the University of Minnesota, said offering a saline shot in such a scenario would be akin to running an experiment in which 'half the parachutes opened and half did not.'
The same logic often applies to clinical trials for new cancer medications, which commonly enroll patients undergoing chemotherapy and radiation as a control group, rather than a placebo.
'It's going to be a little harder to see the effect because you're getting some benefit from the control group,' said Dr. Caplan, the bioethicist.
'But it's wrong to say, 'Well, sorry, you have to die faster if you're assigned to the placebo.''

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kennedy names 8 vaccine committee replacements, including COVID shot critic
Kennedy names 8 vaccine committee replacements, including COVID shot critic

Associated Press

time16 minutes ago

  • Associated Press

Kennedy names 8 vaccine committee replacements, including COVID shot critic

NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. Kennedy's decision to 'retire' the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Kennedy made the announcement in a social media post on Wednesday. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. ___ Associated Press reporter Amanda Seitz contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant
Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant

Geek Tyrant

time21 minutes ago

  • Geek Tyrant

Laika HIres SUSPIRIA Writer to Script Travis Knight's Surreal Stop-Motion Adaptation of PIRANESI — GeekTyrant

Laika's adaptation of Susanna Clarke's mind-bending fantasy novel Piranesi just took a major step forward with the hiring of acclaimed screenwriter Dave Kajganich to handle the script. Kajganich, known for his work on Suspiria , Bones and All , and AMC's The Terror , is currently collaborating with some of the most respected directors in the industry, including Barry Jenkins, Ridley Scott, and Edward Berger. Now, he'll bring his talents and skills to Laika's ambitious stop-motion take on Clarke's beloved novel. 'Piranesi changed my soul and is one of the books in all the world, of any era, I most cherish,' Kajganich said in a statement. 'Having Travis' and Susanna's trust in adapting it is something I take as an honor of the highest order. They are two of the loveliest, smartest, and most humane people you can imagine, so all of this is an actual dream coming true for me.' First announced in June 2024, Piranesi will be directed by Laika President & CEO Travis Knight, who previously helmed the Oscar-nominated Kubo and the Two Strings and the upcoming Wildwood . The project marks a return to the studio's roots in stop-motion storytelling, even as they continue branching out into live-action. The story for Piranesi is set in a dreamlike alternative reality, and it follows Piranesi, 'whose house is no ordinary building: its rooms are infinite, its corridors endless, its walls are lined with thousands upon thousands of statues, each one different from all the others. 'Within the labyrinth of halls, an ocean is imprisoned; waves thunder up staircases, rooms are flooded in an instant. But Piranesi is not afraid; he understands the tides as he understands the pattern of the labyrinth itself. He lives to explore the house.' There is one other person in the house, 'a man called The Other, who visits Piranesi twice a week and asks for help with research into A Great and Secret Knowledge. 'But as Piranesi explores, evidence emerges of another person, and a terrible truth begins to unravel, revealing a world beyond the one Piranesi has always known.' Since its release, Clarke's novel has become a literary phenomenon, selling over four million copies and winning the 2021 Women's Prize for Fiction. Its meditative tone, philosophical depth, and strange beauty seem tailor-made for Laika's visual storytelling. Knight previously shared in a statement: ' Piranesi is a treasure, and very dear to me. As a filmmaker, I can scarcely imagine a more joyful experience than wandering through the worlds Susanna dreamed into being. 'She's one of my all-time favorite authors, and with Piranesi , Susanna has created a beautiful, devastating and ultimately life-affirming work of art. I'm humbled that she chose LAIKA as her home.' Kajganich is also working on Brad Pitt's The Riders , he's also scripting Be My Baby , a Ronnie Spector biopic for A24, with Zendaya set to star and Barry Jenkins directing. While Laika continues to push further into live-action—with projects like Atmosphere from Anna Boden and Ryan Fleck, and Crumble from Brian Duffield and producers Phil Lord and Chris Miller, the studio hasn't lost sight of what made them a fan favorite in the first place: bold, stylized stop-motion animation that tell stories with emotional weight. Source: Deadline

Taletrectinib Approved for NSCLC
Taletrectinib Approved for NSCLC

Medscape

time40 minutes ago

  • Medscape

Taletrectinib Approved for NSCLC

The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store